Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Benobio Co. Ltd. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, showing that each examiner is handling 1 matter for the company. Despite the involvement of 2 distinct examiners, all prosecution activity is centralized within 1 distinct art unit. This concentration suggests a specific focus for the company's current intellectual property efforts in the Biotechnology & Pharmaceuticals sector.
BAHTA, MEDHANIT W serves as the busiest examiner for the portfolio. This examiner is currently managing 1 busiest examiner pending action. This represents 1 of the total 2 pending office actions currently facing the company. The presence of 2 distinct examiners for the current workload indicates a distributed workload across the 1 distinct art unit involved. Practitioners should note that while the examiners differ, the administrative oversight remains within the specified unit for all current Biotechnology & Pharmaceuticals filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAHTA, MEDHANIT W | 1 | 80.6% | +28.2% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711951 | NOVEL QUINIZARIN DERIVATIVE AND PREPARATION METHOD THEREOF | BAHTA, MEDHANIT W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711951 | NOVEL QUINIZARIN DERIVATIVE AND PREPARATION METHOD THEREOF | BAHTA, MEDHANIT W | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711951 | NOVEL QUINIZARIN DERIVATIVE AND PREPARATION METHOD THEREOF | BAHTA, MEDHANIT W | — | §102§103§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18602668 | NOVEL CARBOXAMIDE REDOX DERIVATIVE OF INHIBITING BET PROTEIN AND COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISEASES USING THE SAME | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Mar 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial